NYSEMKT: CHROChannel Therapeutics Corp Stock
$1.17+0.02 (+1.74%)
Updated Jun 23, 2025
CHRO Price
$1.17
Fair Value Price
N/A
Market Cap
$7.72M
52 Week Low
$0.45
52 Week High
$3.80
P/E
-0.94x
P/B
-1.84x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$7.36M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.22
Operating Cash Flow
-$4M
Beta
1.22
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CHRO's potential to beat the market
- CHRO doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CHRO
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.83 | A | |
| $43.37 | A | |
| $22.12 | A |
Be the first to know about important CHRO news, forecast changes, insider trades & much more!
CHRO News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CHRO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CHRO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CHRO is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
CHRO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more CHRO due diligence checks available for Premium users.
Valuation
CHRO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.94x
Industry
-119.29x
Market
31.56x
CHRO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.84x
Industry
4.42x
CHRO's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.0M
Profit Margin
0%
CHRO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$911.2k
Liabilities
$5.1M
Debt to equity
-1.22
CHRO's short-term liabilities ($5.11M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CHRO's short-term assets ($911.18k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CHRO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CHRO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$632.1k
Investing
$0.0
Financing
$250.0k
CHRO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CHRO vs Biotech Stocks
Channel Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.